Please login to the form below

Not currently logged in
Email:
Password:

Data shows positive results for Champix

Smokers who took Pfizer's Champix were more successful in quitting smoking and abstaining compared with those taking a placebo

Results from a new study show smokers who took Pfizer's Champix (varenicline) were 33.5 per cent more successful in quitting smoking and abstaining during the last four weeks of treatment compared with those taking a placebo.

The multi-centre, double-blind study comprised 499 adult smokers, who had smoked at least 10 cigarettes per day before enrolment, with mild-to-moderate chronic obstructive pulmonary disease (COPD) – a condition that up to half of all people who smoke may eventually develop.

"Quitting smoking is of paramount importance for all smokers, particularly those with a smoking-related illness, such as COPD," said Dr Donald Tashkin, study investigator, emeritus Professor of medicine at University of California, Los Angeles.

COPD is characterised by progressive airflow limitation that results in symptoms such as difficulty in breathing, cough and increased production of sputum. It currently affects 210 million people worldwide and according to the American Lung Assoication, is expected to become the third leading cause of death in the world by 2030.

Professor Leonardo Fabbri, study investigator and Professor of Respiratory Medicine at the University of Modena and Reggio Emilia, said: "Healthcare professionals play a critical role in counselling and supporting patients to stop smoking in order to prevent the development of COPD and other severe chronic diseases, or slow their progression. We must act now to reduce the burden of these devastating diseases across Europe."

5th November 2009

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
VISFO

A team of strategic decision specialists with over 30+ years in the pharma space, we give you confidence through experience....

Latest intelligence

Personalised medicine: driving a need for greater diversity in clinical trials
Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...